|
CCK-SAP References
|
2010
See: Society for Neuroscience 2010 Abstracts
2009
Zhang W, Gardell S, Zhang D, Xie JY, Agnes RS, Badghisi H, Hruby VJ, Rance N, Ossipov MH, Vanderah TW, Porreca F, Lai J (2009) Neuropathic pain is maintained by brainstem neurons co-expressing opioid and cholecystokinin receptors. Brain 132:778-787. (Targeting Trends online summary)
See also: Society for Neuroscience 2009 Abstracts
2008
See: Society for Neuroscience 2008 Abstracts
2005
See: Society for Neuroscience 2005 Abstracts
2004
Porecca F, Hruby V, Lai J (2003) Targeting Tests: CCK-SAP in binding studies. Targeting Trends 4(3):5.
2003
Xie Y, Vanderah TW, Ossipov MH, Lai J, Porreca F (2003) A single rostral ventromedial medulla (RVM) treatment with cholecystokinin-saporin (CCK-SAP) prevents the development of opioid-induced paradoxical pain and spinal morphine antionociceptive tolerance. Soc Neurosci Mtg, New Orleans, LA, Abstract #177.4.
Zhang J, Speth RC, Simasko S, Ritter RC (2003) Hypothalamic injection of targeted toxin for cholecystokinin receptive neurons leads to increased 24 hour food intake and weight gain. Soc Neurosci Mtg, New Orleans, LA, Abstract #830.3.
Treece BR, Speth RC, Ritter RC, Burns GA (2003) Altered CCK binding in the dorsal vagal complex following cytotoxic lesion of the nodose ganglion. Soc Neurosci Mtg, New Orleans, LA, Abstract #830.5.